Travere Therapeutics' Q3 revenue surges on FILSPARI growth

Travere Therapeutics

30/10/2025 21:01

Overview

Travere Q3 2025 total revenue rose to $164.9 mln, driven by FILSPARI sales growth

FILSPARI U.S. net product sales grew 155% yr/yr to $90.9 mln in Q3 2025

Travere achieved $25.7 mln net income in Q3 2025, reversing a loss from prior year

Outlook

Travere expects FDA approval for FILSPARI in FSGS by January 2026

Travere aims to restart HARMONY Study of pegtibatinase in 2026

Result Drivers

FILSPARI SALES GROWTH - FILSPARI U.S. net product sales increased 155% yr/yr to $90.9 mln, driven by continued uptake among prescribers

MARKET ACCESS MILESTONE - $40 mln market access milestone from CSL Vifor recognized in Q3 2025, enhancing financial results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$113.15 mln
Q3 EPS
$0.28
Q3 Net Income
$25.70 mln
Q3 Operating Expenses
$139.92 mln
Q3 Operating Income
$24.93 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Travere Therapeutics Inc is $35.00, about 14.3% above its October 29 closing price of $29.98

Press Release: ID:nBw5HdTt4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)